Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival I

[News]

Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer.

More... (http://www.medicalnewstoday.com/articles/158794.php)